Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...
Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...
CNBC's Jim Cramer reports on a study from Cornell and its impact on the stock market. Biden blocks U.S. Steel takeover by ...
Twisted Sifter on MSN5h
Researchers Don’t Believe The Hype Behind All Of The Studies Claiming Massive Health Benefits From GLP-1sWe don’t have any long-term studies at this point, but all of the ones that have come out point not only to the use of the ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback